The agent presented herein is an effective and safe sugar-derivative, for treatment of common colds induced by human rhinoviruses. It targets the life-cycle of the virus without major side effects for the patient, and could be applied in a nasal spray as a single compound medicament or in combination with already existing, conventional decongestant formulations of sprays against common cold.

Innovations offered:

• Anti-viral agent stops virus proliferation
• Efficient & safe agent Low cost of compound
• High compatibility with other therapies
• Global market Ready-to-use medication
• Low probability of resistance development

Currently:

Preferred Cooperation:

□ Commercial Agreement with technical assistance

□ Technical Cooperation Agreement

□ Financial Investment Agreement

□ Joint Venture

R Licensing Agreement

□ Manufacturing Agreement

□ Research Collaboration Agreement

□ Services Agreement

Type of Partner sought: